Lost Investment in Gossamer Bio, Inc. (GOSS)? Levi & Korsinsky Launches Securities Fraud Investigation

Core Viewpoint - Gossamer Bio, Inc. is under investigation by Levi & Korsinsky for potential violations of federal securities laws, particularly related to the results of its pivotal Phase 3 trial for the drug Seralutinib [1]. Group 1: Company Overview - Gossamer Bio's lead pipeline candidate is Seralutinib, which was evaluated in the PROSERA study for pulmonary arterial hypertension [2]. - The PROSERA trial reached its planned enrollment target, but the primary efficacy endpoint did not achieve the prespecified level of statistical significance [3]. Group 2: Management Statements - During the Q1 2025 earnings call, CEO Faheem Hasnain expressed optimism about the trial results, stating that the baseline characteristics were "precisely what we have targeted" and that the company had "over 90% power given the sample size" [3].